With Audentes Buyout, Astellas Poised to Position “Genetic Regulation” as 5th Biz Pillar

Astellas Pharma Corporate Executive Vice President Naoki Okamura Astellas Pharma is acquiring San Francisco-based Audentes Therapeutics for roughly US$3 billion in a bid to establish what it dubs “genetic regulation” as the fifth primary focus of its business based on...read more